We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALHC icon
126
Alignment Healthcare
ALHC
$2.83B
– –
-791,000
Closed -$13.9M
AMGN icon
127
Amgen
AMGN
$234B
– –
-39,900
Closed -$14M
JBIO
128
Jade Biosciences
JBIO
$1.33B
– –
-185,011
Closed -$2.6M
AVTX icon
129
Avalo Therapeutics
AVTX
$1.05B
– –
-475,165
Closed -$7.09M
CCCC icon
130
C4 Therapeutics
CCCC
$474M
– –
-856,353
Closed -$2.25M
CGEM icon
131
Cullinan Oncology
CGEM
$1.4B
– –
-243,006
Closed -$3.45M
CMPS
132
Compass Pathways
CMPS
$1.9B
– –
-1,150,646
Closed -$6.36M
DHR icon
133
Danaher
DHR
$152B
– –
-265,800
Closed -$50.4M
ESPR
134
DELISTED
Esperion Therapeutics
ESPR
– –
-10,570,300
Closed -$29M
GILD icon
135
Gilead Sciences
GILD
$181B
– –
-59,600
Closed -$8.31M
HRTX icon
136
Heron Therapeutics
HRTX
$62M
– –
-9,816,940
Closed -$7.85M
KALV
137
DELISTED
KalVista Pharmaceuticals
KALV
– –
-94,400
Closed -$1.9M
MDXH icon
138
CALL
MDxHealth
MDXH
$68.8M
– –
-124,306,000
Closed -$286M
PFE icon
139
Pfizer
PFE
$159B
– –
-1,946,500
Closed -$54.7M
QGEN icon
140
CALL
Qiagen
QGEN
$8.9B
– –
-250,000
Closed -$10M
RCEL icon
141
CALL
Avita Medical
RCEL
$320M
– –
-40,966,100
Closed -$154M
RCEL icon
142
Avita Medical
RCEL
$320M
– –
-544,895
Closed -$42.5M
REGN icon
143
Regeneron Pharmaceuticals
REGN
$81.8B
– –
-14,700
Closed -$11.4M
SLNO
144
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-100,000
Closed -$3.35M
VTGN icon
145
VistaGen Therapeutics
VTGN
$11.2M
– –
-3,060,000
Closed -$1.75M
BTSG icon
146
BrightSpring Health Services
BTSG
$11.7B
– –
-497,800
Closed -$21.2M
CARL
147
Carlsmed
CARL
$461M
– –
-1,252,600
Closed -$11.3M
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.